Please type a plus sign (+) inside this box -> + Under the Paperwork Reduction Act of 1995, no persons are required to res

Sheet

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

of

(use as many sheets as necessary)

-	Con	nplete if Known	76
	Application Number	09/435,471	2
	Filing Date	November 8, 1999	4
	First Named Inventor	Denise R. Cooper	Ĭ
	Group Art Unit	1632	3
	Examiner Name	Anne Marie Baker	33
_	Attorney Docket Number	USF-T135	76
			_

Silee			<del></del>
		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
Amz	R1	AMARA, F.M. et al. "Defining a Novel cis-Element in the 3'-Untranslated Region of Mammalian Ribonucleotide Reductase Component R2 mRNA" J. Biol. Chem., August 1996, 271(33):20126-20131.	
1	R2	BLOBE, G.C. et al. "Protein Kinase C βII Specifically Binds to and Is Activated by F-actin" J. Biol. Chem., June 1996, 271(26):15823-15830.	
		CAÑETE-SOLER, R. et al. "Characterization of Ribonucleoprotein Complexes and Their Binding Sites on the Neurofilament Light Subunit mRNA" J. Biol. Chem., May 1998, 273(20):12655-12661.	
	R3	CHALFANT, C.E. et al. "Regulation of Alternative Splicing of Protein Kinase Cβ by Insulin" J. Biol. Chem., June 1995, 270(22):13326-13332.	
	R4	HARA, K. et al. "1-Phosphatidylinositol 3-kinase activity is required for insulin-stimulated glucose transport but not for RAS activation in CHO cells" <i>Proc. Natl. Acad. Sci., USA</i> , August 1994, 91:7415-7419.	
	R5	MCCLAIN, D.A. et al. "Glucose and glucosamine regulate growth factor gene expression in vascular smooth muscle cells" <i>Proc. Natl. Acad. Sci., USA</i> , September 1992, 89:8150-8154.	
	R6	NAKSHATRI, H. and P. BHAT-NAKSHATRI "Multiple parameters determine the specificity of transcriptional response by nuclear receptors HNF-4, ARP-1, PPAR, RAR and RXR through common response elements" <i>Nucleic Acids Res.</i> , 1998, 26(10):2491-2499.	
	R8	NIINO, Y.S. et al. "Positive and Negative Regulation of the Transcription of the Human Protein Kinase C ß Gene" J. Biol. Chem., March 1992, 267(9):6158-6163.	
		OBEID, L.M. et al. "Cloning and Characterization of the Major Promoter of the Human Protein Kinase C β Gene" J. Biol. Chem., October 1992, 267(29):20804-20810.	
	R9	PALMER, R.H. et al. "Activation of PRK1 by Phosphatidylinositol 4,5-Bisphosphate and Phosphatidylinositol 3,4,5-Trisphosphate" J. Biol. Chem., September 1995, 270(38):22412-22416.	
R10		PROKIPCAK, R.D. et al. "Purification and Properties of a Protein That Binds to the C-terminal Coding Region of Human c-myc mRNA" J. Biol. Chem., March 1994, 269(12):9261-9269.	T
	R11	QUILLIAM, L.A. et al. "Isolation of a NCK-associated Kinase, PRK2, an SH3-binding Protein and Potential Effector of Rho Protein Signaling" <i>J. Biol. Chem.</i> , November 1996, 271(46):28772-28776.	
Ama	R12	RON, D. et al. "Cloning of an intracellular receptor for protein kinase C: A homolog of the β subunit of G proteins" Proc. Natl. Acad. Sci. USA, February 1994, 91:839-843.	

Everniner	1 / 1	Date	10/12/02
Examiner	Anne-marie dalk	Considered	12/19/02
Signature	Anne-Marie date	Considered	
( Signature			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (08-00)

Please type a plus sign (+) inside this box —> +

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complet\_ if Known Substitute for form 1449B/PTO **Application Number** 09/435.471 INFORMATION DISCLOSURE STATEMENT BY APPLICANT November 8, 1999 **Filing Date** Denise R. Cooper First Named Inventor 1632 **Group Art Unit** (use as many sheets as necessary) Anne Marie Baker **Examiner Name Attorney Docket Number USF-T135** 2

MARK			_
		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		ROSS, J. "mRNA Stability in Mammalian Cells" Microbiology Reviews, September 1995, 59(3):423-450.	
Ama	R14		
	13	SAYESKI, P.P. and J.E. KUDLOW "Glucose Metabolism to Glucosamine Is Necessary for Glucose Stimulation of	
Ama	R15	Transforming Growth Factor-α Gene Transcription" J. Biol. Chem., June 1996, 271(25): 15237-15243.	
Amz	R16	VINCENT, S. and SETTLEMAN, J. "The PRK2 Kinase Is a Potential Effector Target of both Rho and Rac GTPases and Regulates Actin Cytoskeletal Organization" <i>Mol. Cell. Biol.</i> , April 1997, 17(4):2247-2256.	
	R17		<u> </u>
	100		
	R18		L
	R19		
	R20		<u> </u>
			İ
	R21		ļ
		RECEIVED	
	R22		
		NOV 2 0 2002	
	R23		├
		TECH CENTER 1600/2900	
	R24		$\vdash$
<del></del>	R25		1
	R26		

Examiner Signature	Anne-Marie Falk	Date Considered	12/13/02

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-00) Approved for use through 10/31/2002. OMB 0651-0031

Rlease type a plus sign (+) inside this box -> + Ppe a plus sign (+) inside this box—— LT U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


10 Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known ubstitute for form 1449B/PTO Application Number 09/435,471 HIFORMATION DISCLOSURE November 8, 1999 Filing Date STATEMENT BY APPLICANT First Named Inventor Denise R. Cooper Group Art Unit 1632 (use as many sheets as necessary) Anne Marie Baker **Examiner Name** 

-	•				Examiner Name	Allie Walle Baker			
Shee	t	1	of	1 ,	Attorney Docket Numbe	r USF-T135	ر 🚾		
			NON P	ATENT LITER	RATURE DOCUMENTS		8 8		
Examiner Initials*	Cite No. 1	item (book	name of the aut k, magazine, jo	ther (îñ CAPITAL jurnat, serial, syn publisher, ci	LETTERS), title of the article nposium, catalog, etc.), date, ty and/or country where publis	e, (when appropriate), title of the page(s), volume-issue number(s) shed.			
Ama	R1	AMANO, M. et al. "Identification of a Putative Target for Rho as the Serine-Threonine Kinase Protein Kinase N Science, February 1996, 271(5249):648-650.  AMARA, F.M. et al. "A cis-trans Interaction at the 3'-Untranslated Region of Ribonucleotide Reductase mRNA Is							
	R2	Regulated by TG	F-β <sub>1</sub> , TGF-β <sub>2</sub> ,	and TGF-β <sub>3</sub> " Bi	ochem. and Biophysical Re	s. Comm., 1996, 226.347-331.	_		
	R3	About?" Matrix Bi	BENBOW, U. and C.E. BRINCKERHOFF "The AP-1 Site and MMP Gene Regulation: What Is All the Fuss About?" <i>Matrix Biology</i> , 1997, 15:519-526.						
		region stability de	eterminant" Ge	enes Dev., 1992	2, 6:642-654.	protein capable of binding to			
	R4	CHUNG, J. et a kinase" Nature, J	<i>al.</i> "PDGF- a July 1994, 370	nd insulin-depo :71-75.	endent pp70 <sup>ssk</sup> activation	mediated by phosphatidylinos	sitol-3-OH		
	R5	HANSEN, W.R. stability element"	et al. "The 3 ' Amer. J. Phy	'-nontranslated siology, July 19	region of rat renal glutami 96, 271:F126-F131.	inase mRNA contains a pH-re	esponsive		
	R6	JIA, Z. "Protein p	hosphatases:	structures and	implications" Biochem. Cell	Biol., 1997, 75:17-26.			
-	R7	KEMP, B.E. and 1990, 15(9):342-		ON "Protein kin	ase recognition sequence n	notifs" Trends Biochem. Sci., S	eptember		
	R8	MUKAI, H. and Highly Homologo	Y. ONO "A Nous to That of	lovel Protein K Protein Kinase	inase with Leucine Zipper-L C" Biochem. Biophsy. Res.	ike Sequences: Its Catalytic [Comm., March 1994, 199(2):85	Domain is 97-904.		
	R9_	NEWTON, A.C.	"Regulation of	f protein kinase	C" Curr. Opin. Cell Biol., 19	97, 9:161-167.			
	R10	NISHIZUKA, Y.	"Studies and F	Perspectives of	Protein Kinase C" Science,	July 1986, 233(4761):305-312.			
	R11	NISHIZUKA, Y. Science, Octobe	"Intracellular er 1992, 258(5	Signaling by 6082):607-614.	Hydrolysis of Phospholipid	s and Activation of Protein I	Kinase C"		
Ama	R12	l .			signaling for sustained cellu	ular responses" <i>FASEB J.</i> , 199	95, 9:484-		

Examiner	Anne-Marie Falk	Date Considered	12/13/02	
[ Signature				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



Please type a plus sign (+) inside this box —> [+]

Noter the Pape	rwork Reduction Act of	995,	no persons are required t	U.S. Patent and Trademar	k Office: U.S. DEPARTMENT OF COMME unless it contains a valid OMB control nur	RCE
- 1	ute for form 1449B/PTO			Complete if Known		
1 1 1 1 7 7	RMATION DI		COLIDE	Application Number	09/435,471	
				Filing Date	November 8, 1999	
	TEMENT BY	API	LICANI	First Named Inventor	Denise R. Cooper	
MARCH CAP	ıse as many sheets a	s ner	resser/)	Group Art Unit	1632	
1.4 A.		0 7700		Examiner Name	Anne Marie Baker	
Sheet	2	of	2	Attorney Docket Number	USF-T135	

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
Ama	R14	OREKHOV, A.N. et al. "Cellular Composition of Atherosclerotic and Uninvolved Human Aortic Subendothelial Intima" Am J. Pathol., 1984, 115:17-24.					
	R15	PALMER, R.H. and P.J. PARKER "Expression, purification and characterization of the ubiquitous protein kinase C-related kinase 1" <i>Biochem. J.</i> , 1995, 309:315-320.					
	R16	PATEL, N.A. et al. "Acute hyperglycemia regulates transcription and posttranscriptional stability of PKCβII mRNA in vascular smooth muscle cells" FASEB J., 1999, 13:103-113.					
	R17	PERROTTI, D. et al. "TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis" <i>The EMBO J.</i> , 1998, 17(15):4442-4455.					
	R18	PREKERIS, R. et al. "Identification and Localization of an Actin-binding Motif That Is Unique to the Epsilon Isoform of Protein Kinase C and Participates in the Regulation of Synaptic Function" J. Cell Biol., January 1996, 132(1-2):77-90.					
	R19	RIDLEY, A.J. et al. "The Small GTP-Binding Protein rac Regulates Growth Factor-Induced Membrane Ruffling" Cell, August 1992, 70:401-410.					
	R20	ROSS, R. "The Pathogenesis of Atherosclerosis—An Update" N. Eng. J. Med., February 1986, 314(8):488-500.					
	R21	SANTEN, R.J. et al. "Atherosclerosis in Diabetes Mellitus. Correlations With Serum Lipid Levels, Adiposity, and Serum Insulin Level" Arch. Intern. Med., December 1972, 130(6):833-843.					
	R22	SCHWARTZ, S.M. et al. "Replication of Smooth Muscle Cells in Vascular Disease" Circ. Res., April 1986, 58(4):427-444.					
	R23	SHIBA, T. et al. "Characterization of the Activation of Protein Kinase C Isoenzymes in the Retina of Diabetic Rats" Diabetes, 1990, 39(Supplement 1):31A. Abstract No. 123.					
V	R24	TAKAI, Y. et al. "Studies on a Cyclic Nucleotide-independent Protein Kinase and Its Proenzyme in Mammalian Tissues" J. Biol. Chem., November 1977, 252(21):7603-7609.					
Ama	R25	WATANABE, G. "Protein Kinase N (PKN) and PKN-Related Protein Rhophilin as Targets of Small GTPase Rho" Science, February 1996, 271(5249):645-648.					
	R26						

Examiner Signature	Anne-marie Jalk	Date Considered	12/13/02
		Ooribiacica	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (08-00) Approved for use through 10/31/2002. OMB 0651-0031

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.